Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants with Advanced or Refractory Tumors
The purpose of this study is to evaluate the safety, tolerability, and antitumor activity of BGB-3245 in participants with advanced or refractory solid tumors
Solid Tumor|B-Raf Mutation-Related Tumors
DRUG: BGB-3245
Phase 1a: Number of Participants and Severity Experiencing Adverse Events (AEs), Up to 30 days after the last dose of study drug|Phase 1a: Number of Participants and Severity Experiencing Serious Adverse Events (SAEs), Up to 30 days after the last dose of study drug|Phase 1a: number of Participants Experiencing AEs meeting protocol defined Dose-Limiting Toxicity (DLT) criteria, From Cycle 1 Day to the end of Cycle 1 (Cycle 1 is 30 days)|Phase 1a: Maximum Tolerated Dose (MTD) of BGB-3245, and the recommended Phase 2 Dose (RP2D) for BGB-3245, The MTD is defined as the highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 33%., From Cycle 1 Day to the end of Cycle 1 (Cycle 1 is 30 days)|Phase 1b: Recommended Phase 2 dose (RP2D) of BGB-3245, The highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 33%, From Cycle 1 Day to the end of Cycle 1 (Cycle 1 is 30 days)|Phase 1b: Objective Response Rate (ORR) as assessed by the investigator, ORR is defined as the percentage of participants with partial or complete response, as assessed by the investigator, Up to 24 months|Phase 1b: Further review of the ORR, ORR is defined as the percentage of participants with partial or complete response in up to 15 participants with tumors harboring BRAF fusion mutations, Up to 24 months
Phase 1a: Overall Response Rate (ORR) as Assessed by the Investigator, Up to 24 months|Phase 1a: Duration of Response (DOR) as Assessed by the Investigator, Up to 24 months|Phase 1a: Clinical Benefit Rate (CBR) as Assessed by the Investigator, Up to 24 months|Phase 1a: Best Overall Response (BOR) as Assessed by the Investigator, Up to 24 months|Phase 1a: Duration of Stable Disease (DSD), Up to 24 months|Phase 1a: Progression Free Survival (PFS), Up to 24 months|Phase 1a: Plasma Concentration of BGB-3245, Within 60 minutes predose up to 72 hours postdose|Phase 1a: Maximum Observed Plasma Concentration (Cmax) of BGB-3245, Within 60 minutes predose up to 72 hours postdose|Phase 1a: Time to Maximum Plasma Concentration (Tmax) of BGB-3245, 60 minutes predose up to 72 hours postdose|Phase 1a: Time Taken for Half the Initial Dose Administered To Be Eliminated From The Body (T1/2) of BGB-3245, 60 minutes predose up to 72 hours postdose|Phase 1a: Area Under the Concentration-Time Curve of 0-infinity Days (AUC0-inf) of BGB-3245, 60 minutes predose up to 72 hours postdose|Phase 1a:Area Under the Concentration-Time Curve of 0-Last hour (AUC0-last) of BGB-3245, 60 minutes predose up to 72 hours postdose|Phase 1a: Drug Clearance (CL/F) of BGB-3245, 60 minutes predose up to 72 hours postdose|Phase 1a: Apparent Volume of Distribution (Vz/F) of BGB-3245, 60 minutes predose up to 72 hours postdose|Phase 1a: Steady State Area Under the Concentration-Time Curve of 0- Last hour (AUCLast, ss) of BGB-3245, 60 minutes predose up to 72 hours postdose|Phase 1a: Steady State Maximum Observed Plasma Concentration (Cmax, ss) of BGB-3245, 60 minutes predose up to 72 hours postdose|Phase 1a: Steady State Time to Maximum Plasma Concentration (Tmax, ss) of BGB-3245, 60 minutes predose up to 72 hours postdose|Phase 1b: Progression-free survival (PFS) as Assessed by the Investigator, Up to 36 months|Phase 1b: Duration of Response (DOR) as Assessed by the Investigator, Up to 24 months|Phase 1b: Disease-Control Rate (DCR) as Assessed by the Investigator, Up to 24 months|Phase 1b: Duration of Stable Disease (DSD) as Assessed by the Investigator, Up to 24 months|Phase 1b: Clinical Benefit Rate (CBR) as Assessed by the Investigator, Up to 24 months|Phase 1b: Overall Survival, Up to 36 months|Phase 1b: Number of Participants Experiencing Adverse Events (AEs), Up to 30 days after the last dose of study drug|Phase 1b: Number of Participants Experiencing Serious Adverse Events (SAEs), Up to 30 days after the last dose of study drug|Phase 1b: Plasma Concentration of BGB-3245, 60 minutes predose up to 3 hours postdose|Phase 1b: Steady State Trough Observed Plasma Concentration (Ctrough, SS) of BGB-3245, 60 minutes predose up to 72 hours postdose
The purpose of this study is to evaluate the safety, tolerability, and antitumor activity of BGB-3245 in participants with advanced or refractory solid tumors